semaglutide and optic neuropathy linked to risk of rare eye condition Wegovy may raise risk of

Diker Cohen T, Rudman Y, Turjeman A, et al

Furthermore, tirzepatide, characterized as a dual agonist targeting GIP and GLP-1, has exhibited efficacy in weight reduction and recently secured approval from the Food and Drug Administration for managing both T2D and obesity [22,25,26]

The GLP-1 is doing the heavy lifting for appetite suppression and weight loss

Labs are not required to begin treatment, and they are not bundled into a plan

The scientific evidence is overwhelming

Patient-safety page describing company testing results on market samples of compounded semaglutide, including impurity levels up to 33%, samples with zero measurable active ingredient, and contamination with trace metals, residual solvents, formaldehyde adducts, and BPC-157